AstraZeneca Pharma India Balance Sheet Health
Financial Health criteria checks 5/6
AstraZeneca Pharma India has a total shareholder equity of ₹7.1B and total debt of ₹45.9M, which brings its debt-to-equity ratio to 0.6%. Its total assets and total liabilities are ₹10.8B and ₹3.7B respectively. AstraZeneca Pharma India's EBIT is ₹1.4B making its interest coverage ratio -4.5. It has cash and short-term investments of ₹5.1B.
Key information
0.6%
Debt to equity ratio
₹45.90m
Debt
| Interest coverage ratio | -4.5x |
| Cash | ₹5.06b |
| Equity | ₹7.12b |
| Total liabilities | ₹3.66b |
| Total assets | ₹10.78b |
Recent financial health updates
No updates
Recent updates
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors
Sep 18
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability
Jun 03Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S
May 22We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease
Apr 04Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Nov 10AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00
Jul 06Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Jun 16Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
Aug 02Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock
Feb 25Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Feb 04Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Jan 18
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years
Dec 31We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability
Dec 13Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching
Nov 25Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay
Nov 07What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Oct 20AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sep 24If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today
Aug 28What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?
Aug 02Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Jul 12Financial Position Analysis
Short Term Liabilities: ASTRAZEN's short term assets (₹9.3B) exceed its short term liabilities (₹3.6B).
Long Term Liabilities: ASTRAZEN's short term assets (₹9.3B) exceed its long term liabilities (₹89.9M).
Debt to Equity History and Analysis
Debt Level: ASTRAZEN has more cash than its total debt.
Reducing Debt: ASTRAZEN's debt to equity ratio has increased from 0% to 0.6% over the past 5 years.
Debt Coverage: ASTRAZEN's debt is well covered by operating cash flow (607.2%).
Interest Coverage: ASTRAZEN earns more interest than it pays, so coverage of interest payments is not a concern.